Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 9 | 2024 | 1008 | 1.820 |
Why?
|
| Pancreatic Neoplasms | 6 | 2024 | 690 | 1.390 |
Why?
|
| Colorectal Neoplasms | 5 | 2025 | 564 | 0.930 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 35 | 0.870 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 73 | 0.850 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 222 | 0.780 |
Why?
|
| Ikaros Transcription Factor | 2 | 2022 | 28 | 0.750 |
Why?
|
| Transaminases | 2 | 2022 | 32 | 0.750 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 154 | 0.730 |
Why?
|
| Anemia | 1 | 2024 | 340 | 0.680 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 248 | 0.640 |
Why?
|
| Safety-net Providers | 1 | 2020 | 52 | 0.640 |
Why?
|
| Needs Assessment | 2 | 2025 | 172 | 0.630 |
Why?
|
| Oncologists | 1 | 2019 | 29 | 0.620 |
Why?
|
| Documentation | 1 | 2019 | 116 | 0.590 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 73 | 0.590 |
Why?
|
| Exophthalmos | 1 | 2018 | 37 | 0.580 |
Why?
|
| Minority Groups | 1 | 2020 | 247 | 0.580 |
Why?
|
| Bacteremia | 2 | 2021 | 403 | 0.570 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 425 | 0.560 |
Why?
|
| Orbital Neoplasms | 1 | 2018 | 65 | 0.560 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 53 | 0.560 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 106 | 0.560 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 329 | 0.550 |
Why?
|
| Orbit | 1 | 2018 | 102 | 0.550 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 109 | 0.550 |
Why?
|
| Rectal Neoplasms | 3 | 2023 | 79 | 0.520 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 84 | 0.510 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 544 | 0.510 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2014 | 4 | 0.470 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2014 | 7 | 0.470 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 19 | 0.460 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 504 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1207 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 724 | 0.410 |
Why?
|
| Physicians | 1 | 2019 | 579 | 0.410 |
Why?
|
| Electronic Health Records | 1 | 2019 | 721 | 0.400 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2018 | 61 | 0.370 |
Why?
|
| Neoplasms | 2 | 2025 | 2760 | 0.360 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 1233 | 0.330 |
Why?
|
| Aged | 13 | 2025 | 19516 | 0.320 |
Why?
|
| Middle Aged | 14 | 2025 | 26569 | 0.300 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1308 | 0.300 |
Why?
|
| Aspergillosis | 2 | 2004 | 43 | 0.290 |
Why?
|
| Adult | 16 | 2025 | 29292 | 0.280 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 548 | 0.280 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 411 | 0.280 |
Why?
|
| Humans | 30 | 2025 | 124005 | 0.270 |
Why?
|
| Paclitaxel | 2 | 2024 | 124 | 0.260 |
Why?
|
| Anal Canal | 2 | 2023 | 80 | 0.260 |
Why?
|
| Female | 16 | 2025 | 66186 | 0.240 |
Why?
|
| Aspergillus | 1 | 2004 | 26 | 0.240 |
Why?
|
| Male | 16 | 2025 | 60908 | 0.240 |
Why?
|
| Mannans | 1 | 2004 | 11 | 0.240 |
Why?
|
| Lung Diseases, Fungal | 1 | 2004 | 31 | 0.230 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 150 | 0.230 |
Why?
|
| Albumins | 1 | 2024 | 87 | 0.220 |
Why?
|
| Health Services Needs and Demand | 1 | 2025 | 171 | 0.220 |
Why?
|
| Bayes Theorem | 1 | 2024 | 282 | 0.200 |
Why?
|
| Communicable Diseases | 1 | 2004 | 160 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 1031 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 509 | 0.190 |
Why?
|
| Blood Culture | 1 | 2021 | 31 | 0.180 |
Why?
|
| DNA Methylation | 2 | 2025 | 1003 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 6461 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1585 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 335 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1134 | 0.170 |
Why?
|
| Stress, Psychological | 1 | 2025 | 540 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 177 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 674 | 0.170 |
Why?
|
| Lymph Nodes | 2 | 2019 | 381 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 174 | 0.170 |
Why?
|
| Fraud | 1 | 2019 | 16 | 0.160 |
Why?
|
| Acute Disease | 2 | 2018 | 1107 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2024 | 677 | 0.160 |
Why?
|
| Medically Uninsured | 1 | 2020 | 73 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 51 | 0.160 |
Why?
|
| Leucovorin | 3 | 2023 | 49 | 0.150 |
Why?
|
| Mass Screening | 2 | 2015 | 781 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 49 | 0.150 |
Why?
|
| Fluorouracil | 3 | 2023 | 126 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 159 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2086 | 0.150 |
Why?
|
| Genetic Testing | 2 | 2015 | 1000 | 0.150 |
Why?
|
| Gastrectomy | 1 | 2019 | 91 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 307 | 0.150 |
Why?
|
| Algorithms | 2 | 2015 | 1605 | 0.140 |
Why?
|
| Myxoma virus | 1 | 2017 | 1 | 0.140 |
Why?
|
| Parvovirus | 1 | 2017 | 8 | 0.140 |
Why?
|
| Orthoreovirus, Mammalian | 1 | 2017 | 7 | 0.140 |
Why?
|
| Measles virus | 1 | 2017 | 10 | 0.140 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 87 | 0.140 |
Why?
|
| Vaccinia virus | 1 | 2017 | 52 | 0.140 |
Why?
|
| Simplexvirus | 1 | 2017 | 104 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2022 | 664 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2021 | 16239 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 865 | 0.130 |
Why?
|
| Ethics, Medical | 1 | 2019 | 395 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 417 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 356 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1102 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 53 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2014 | 99 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2017 | 605 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 154 | 0.110 |
Why?
|
| Microscopy | 1 | 2014 | 117 | 0.110 |
Why?
|
| Esophagoscopy | 1 | 2014 | 156 | 0.110 |
Why?
|
| Organ Sparing Treatments | 2 | 2023 | 35 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1084 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 227 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2023 | 77 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1688 | 0.090 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 103 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1223 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2420 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2023 | 354 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 865 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2023 | 12262 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 1474 | 0.060 |
Why?
|
| Foodborne Diseases | 1 | 2004 | 11 | 0.060 |
Why?
|
| Meningococcal Vaccines | 1 | 2005 | 30 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2004 | 15 | 0.060 |
Why?
|
| Galactose | 1 | 2004 | 54 | 0.060 |
Why?
|
| Splenectomy | 1 | 2005 | 64 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 258 | 0.060 |
Why?
|
| Young Adult | 4 | 2019 | 8971 | 0.060 |
Why?
|
| Itraconazole | 1 | 2003 | 25 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 47 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 168 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 585 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 86 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 329 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2035 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 388 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 274 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2005 | 373 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 22 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2004 | 280 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 230 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2004 | 310 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 166 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 1417 | 0.050 |
Why?
|
| Psychometrics | 1 | 2025 | 666 | 0.050 |
Why?
|
| Incidence | 3 | 2017 | 3134 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2003 | 288 | 0.050 |
Why?
|
| Standard of Care | 1 | 2022 | 129 | 0.040 |
Why?
|
| Caregivers | 1 | 2025 | 557 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 240 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 2037 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4605 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 65 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 89 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 86 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 140 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 133 | 0.040 |
Why?
|
| United States | 3 | 2019 | 10853 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 1421 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1490 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 272 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 99 | 0.040 |
Why?
|
| General Surgery | 1 | 2019 | 203 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 418 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 271 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3413 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 1198 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 33994 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1252 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 4768 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1349 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3681 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1172 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3046 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1527 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1898 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2137 | 0.030 |
Why?
|
| Adolescent | 2 | 2019 | 19222 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3580 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2005 | 25 | 0.020 |
Why?
|
| Drug Resistance, Fungal | 1 | 2003 | 24 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3146 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 775 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 10239 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 543 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3056 | 0.010 |
Why?
|